Transgene : TG4001 has a move to make
>Convincing signs in an aggressive type of cancer - The poster for the phase I study evaluating TG4001 was published yesterday at the ESMO congress. Note that we already knew the headlines that were presented in an abstract last week. In this trial, which aimed to mainly evaluate the safety of TG4001 with Opdivo, we note three partial responses leading to a 30% reduction in tumour size (at the highest dose) according to the RECIST score in patients with papillomavirus...Transgene is a biopharmaceutical company that designs and develops immunotherapy and virotherapy products for the treatment of cancers and infectious diseases. Co. is developing three anti-cancer products that are in clinical trials: (cancer of the lungs, liver and oropharynx); two anti-infectious immunotherapy products also in clinical trials: (hepatitis B and C). Co. also has products in the pre-clinical development stage. Co. operates in a single business segment, the research and development of therapeutic vaccines and immunotherapy products. Co. does not have any products on the market. Substantially all of its operations are conducted in France.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.